Circadian Technologies (ASX:CIR) has started offering its LAM diagnostic, which is offered as a laboratory test compliant with CAP (College of American Pathologists) CLIA regulations.
The company is partnering with the Children’s Hospital Medical Centre to offer the test, with tests expected to exceed 25,000 in the medium term.
LAM is a serious but often misunderstood or misdiagnosed disease, and mainly effects women of child bearing age.
Robert Klupacs, chief executive officer for Circadian, said “Circadian is very excited about the launch of this test.
"It is the first product to emerge from our extensive VEGF technology portfolio, and hopefully the first of many, to become available from the range of diagnostics in development by Circadian and our partners."
Diagnostics are an important part of Circadian’s business which are progressing in parallel with the drug discovery activity.
Most importantly, they provide the stong potential for an early source of revenue, and complement the product portfolio.